

**Stem Cell Reports, Volume 3**

**Supplemental Information**

**Neural Stem Cell Differentiation Is Dictated by Distinct  
Actions of Nuclear Receptor Corepressors and Histone  
Deacetylases**

**Gonçalo Castelo-Branco, Tobias Lilja, Karolina Wallenborg, Ana M. Falcao, Sueli C. Marques, Aileen Gracias, Derek Solum, Ricardo Paap, Julian Walfridsson, Ana I. Teixeira, Michael G. Rosenfeld, Kristen Jepsen, and Ola Hermanson**

## SUPPLEMENTARY METHODS

**OPC cultures.** Oli-neu cells were plated in flasks coated with 0,01% poly-L-lysine (Sigma-Aldrich) and expanded in Sato media (with 340ng/ml T3 and 400 ng/ml L-thyroxine, Sigma-Aldrich) supplemented with 1% horse serum (Invitrogen). Cells were passaged with trypsin (Invitrogen) and DNase I (Roche), and differentiated in the presence of 1mM dibutyryl cAMP (Sigma-Aldrich). For lipofection or differentiation assays, Oli-neu cells were plated at the following densities:  $114 \times 10^3$  cells in 35 mm plates (Corning) or  $300 \times 10^3$  cells in 60 mm plates (Corning). For CHIP analysis, cells were expanded in 10c The postnatal OPC cells were plated in flasks coated with poly-L-ornithine and fibronectin (Sigma-Aldrich) and expanded in N1 media supplemented with FGF-2 (10ng/ml) and PDGF-BB (10ng/ml, both from R&D Systems). Cells were passaged with trypsin (Invitrogen) and DNase I (Roche), and differentiated by removal of the mitogens. For lipofection or differentiation assays, Oli-neu cells were plated at  $200 \times 10^3$  cells in 35 mm plates (Corning). For CHIP analysis, cells were expanded in 10cm plates (Corning) and allowed to grow until confluency, before collection. m plates (Corning) and allowed to grow until confluency, before collection.

**Primer design.** Genbank cDNA sequences or conserved regulatory sequences identified in ECR browser (Loots and Ovcharenko, 2004) were used to design gene specific primers in Primer Express 2.0 (PE Applied Biosystems) or in the Universal ProbeLibrary Assay Design Center (Roche Applied Science). The specificity of PCR primers was determined by BLAST run of the primer sequences. All primers were purchased from MWG Biotech. Primer sequences can be provided upon request.

**Immunoblotting.** Cells were rinsed twice with cold PBS protease inhibitor (Complete, Roche), collected by scraping and pelleted at 1000 rpm for 2 minutes at 4°C. The cells were then resuspended in NETN buffer (20mM HEPES, 150mM NaCl, 1mM EDTA and 0,5% NP40) with protease inhibitor (Complete, Roche), homogenized by passing through a 21G needle and centrifuged at 13 000 rpms for 15 minutes at 4°C. Supernatant was collected and protein concentration measured. 40µg of protein was mixed with loading buffer containing SDS, glycerol, beta-mercaptoethanol and DTT and run in 12% ReadyGel Tris-HCl (Biorad). After electrophoresis and western blot, cells were probed with the following antibodies: α-HDAC2 (2540), α-HDAC3 (2632), from Santa Cruz Biotechnology, α-Sox10 (AF2864, R&D Systems). After incubation with anti-rabbit and anti-goat HRP antibodies (Chemicon, 1:2000-1:5000), blots were developed using RPN2106 ECL Western Blotting detection reagents, from GE Healthcare.

**Reverse Transcription.** Total RNA was isolated from NSCs, Oli-neu and CG4 cells using RNeasy extraction kit (Qiagen), with DNase treatment in-column. 200ng of total RNA were used with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems), according to the manufacture's instructions and with each sample being equally divided in two tubes, a cDNA reaction tube and a negative control tube (RT-). Alternatively, Superscript II reverse transcriptase (Invitrogen) was used. Before q-PCR analysis, both cDNA and RT- were then diluted 25 or 50 times, in DNase and RNase free dH<sub>2</sub>O (Invitrogen).

**qPCR.** qRT-PCR reactions were performed in duplicates for each sample. Each PCR reaction had a final volume of 25  $\mu$ l and 5 $\mu$ l of 25x- or 50x- diluted cDNA. RT- was run for a few samples in each run to discard genomic DNA amplification. Platinum Quantitative PCR SuperMix-UDG (Invitrogen) was used, according to the manufacture's instructions (but with a 4X dilution from the original mastermix, instead of 2X). The following thermo cycling program was used: 50°C for 2 minutes, 94°C for 2 minutes and then 40 cycles of 94° C for 30 s, 59/60°C for 30s and 72° C for 30s on the ABI PRISM 7000 Detection System (PE Applied Biosystems, Foster City, CA, USA). A melting curve was obtained for each PCR product after each run, in order to confirm that the SYBR Green signal corresponded to a unique and specific amplicon. Random PCR products were also run in a 2-3% agarose gel to verify the size of the amplicon. Standard curves were generated for every real time PCR run and were obtained by using serial 3-fold dilutions of a sample containing the sequence of interest. Their plots were used to convert Cts (number of PCR cycles needed for a given template to be amplified to an established fluorescence threshold) into arbitrary quantities of initial template for a given sample. The expression levels were then obtained by dividing the quantity by the value of the housekeeping gene, Tata binding protein (TBP). In a few instances, hypoxanthine guanine phosphoribosyl transferase (HPRT) was used as housekeeping gene. For each individual experiment, sample values were normalized by the average sample value of the experiment. TBP assays were run at the beginning and in the middle of assays, to verify the integrity of the samples, and every time the samples were freezed/thawed. Alternatively, the delta-delta Ct method was used.

**Immunocytochemistry and cell quantification.** Cells were fixed in 10% formalin for 10 minutes and washed in PBS with 0.1% Triton X100, 3 times for 5 minutes. After an overnight incubation at 4°C with the primary antibody (rat anti-myelin basic protein monoclonal (MAB386, Chemicon, 1:250), mouse RIP (Developmental Studies Hybridoma Bank, 1:100) in PBS with 1-3% bovine serum albumin (BSA), 0.1% Triton X100 and 0,02% sodium azide, the cells were washed six times for 5 minutes with PBS with 0.1% Triton X100. They were then incubated for 2 hours with an appropriate secondary antibody (donkey or goat anti-mouse and anti-rat conjugated to Alexa 488 and Alexa 546/594, 1:500, Molecular Probes/Invitrogen) in PBS with 1% bovine serum albumin (BSA) and 0.1% Triton X100. After 3 washes for 5 minutes with PBS, the cells were either counterstained with 4',6-diamidino-2-phenylindole (DAPI, Vector Laboratories). Images were acquired with a Zeiss Axiokop 2 microscope (objectives: 5x/0,25, Zeiss Fluar ∞/0,17, 10x/0,3, Zeiss NeoFluar ∞/0,17 and 20x/0,50, Zeiss Neo-Fluar ∞/0,17) and collected with a Zeiss AxioCam camera MRm (with Axiovision Rel 4.6 software). Images were processed with Adobe Photoshop CS2 version 9.0.2 and panels were assembled with Adobe Illustrator CS2 11.0.1. Quantitative immunocytochemical data of NSCs cultures represents means ± s.e.m., obtained from 3 non-overlapping 10x fields in each condition, from 3 separate independent experiments, after normalization with the number of DAPI positive cells present in the same fields. For DAPI quantification, a macro was programmed in Image J, with the following tools: "Find Edges", "Threshold", and "Analyze Particles". Cells present in clusters were counted manually with the Cell Counter Plug-in. Similar procedures were used in Fig. 4b, in which for each individual experiment, sample values were normalized by the average sample value of the experiment. Oligodendrocyte radius was measured with the AxioVision

Rel 4.6 software. MBP+ cells from 3 non-overlapping 10x field images were counted, in 4 independent experiments. For oli-neu cells, the total number of MBP+ cells with elaborate processes (>3) were counted in the entire 35mm plate in each independent experiment and then normalized by the number of DAPI+ cells in 5 random fields. For each individual experiment, sample values were normalized by the average sample value of the experiment.

**RNA profiling.** RNA was prepared from cultured cells of E12.5 cortex from wild-type NSCs 3 h after plating. RNA quality was assessed using the Agilent Bioanalyser 6000 Pico LabChip. 100 ng of total RNA was labelled with Cy-3 or Cy-5 using the Agilent Low RNA Input Fluorescent Linear Amplification Kit. A dye-swap design was employed. Labeled cDNA was hybridized to the Agilent 44K Whole Mouse Genome Array. Data was collected using the Agilent Microarray Scanner and Feature Extraction Software, using a Lowess option with spatial detrend to extract genes of interest with more confidence than through the use of fold-change only. Experiments were performed in triplicate, with litter-matched wild-type and mutant samples.

**ChIP-seq in cortically-derived embryonic NSCs.** Chromatin immunoprecipitation (ChIP) was performed following the High Cell ChIP kit # protocol from Diagenode. Five micrograms of anti-HDAC antibodies were used in each IP. Initial ChIP analysis was done with qPCR using Invitrogen Platinum SYBR Green qPCR Supermix-UDG together with site-specific primers. Chromatin immunoprecipitation followed by next generation sequencing (ChIP-Seq) was performed essentially as described before (Füllgrabe et al, 2013; Heldring et al., 2014). For ChIP-seq analysis, 5 mg of

chromatin was used in 2 separate IP's and combined into one elution. Subsequently, the DNA sequencing library was made using a kit from Illumina, except Illumina TruSeq adaptors were used to enable multiplexing. The library was analyzed by Solexa/Illumina Hi-seq. After prefiltering the raw data by removing sequenced adaptors and low-quality reads, the sequence tags were aligned to the human genome (assembly hg19) with a Bowtie alignment tool (Langmead et al., 2009). To avoid any PCR-generated spikes, we allowed only one read per chromosomal position and thus eliminated PCR bias. From the filtered raw data, 2 million unique reads per sample were used for peak detection. Peak detection was performed using the CisGenome program (Ji et al., 2008) with a 2-sample analysis where sequenced input (1%) was used as a negative control. Peaks were called with a window statistic cutoff of 3 and a log<sub>2</sub> fold change of 2.

## REFERENCES

Füllgrabe, J., Lynch-Day, M.A., Heldring, N., Li, W., Struijk, R.B., Ma, Q., Hermanson, O., Rosenfeld, M.G., Klionsky, D.J., and Joseph, B. (2013). The histone H4 lysine 16 acetyltransferase hMOF regulates the outcome of autophagy. *Nature* 500, 468-471.

Heldring, N., Nyman, U., Lönnerberg, P., Önnestam, S., Herland, A., Holmberg, J., and Hermanson, O. (2014). NCoR controls glioblastoma tumor cell characteristics. *Neuro-Oncol.* 16, 241-249.


Ji, H., Jiang, H., Ma, W., Johnson, D.S., Myers, R.M., and Wong, W.H. (2008) An integrated software system for analyzing ChIP-chip and ChIP-seq data. *Nat. Biotechnol.* 26, 1293–1300.

Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009) Ultrafast and

memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* *10*, R25.

Loots, G.G., and Ovcharenko, I. (2004). rVISTA 2.0: evolutionary analysis of transcription factor binding sites. *Nucleic Acids Res.* *32*, W217-221.






**Supplementary Figure S1**

**A.** Bars representing the levels of *Hdac2* (left panel) and *Hdac3* (right panel) mRNA as assessed by qRT-PCR after siRNA against *Hdac2* (siHDAC2) and *Hdac3* (siHDAC3).

**B.** Lipofection of *Hdac2*, *Hdac3* and *Sox10* siRNAs in Oli-neu and CG4 cells led to a specific decrease in the levels of the respective proteins, 1 DIV after lipofection, as assessed by immunoblot with antibodies against HDAC2, HDAC3 and SOX10. Equal amounts of protein were loaded.

**A-B:** n=3-5 independent experiments. Error bars = S.E.M..




**Supplementary Figure S2**

**A.** qRT-PCR analysis of oligodendrocyte-associated transcripts revealed that HDAC inhibitor VPA in neural stem cell cultures treated with bFGF, PDGF, and IGF-2 (OLPm) led to decreased transcription of *MBP*, *CNPase*, *Nkx2.2*, *Sox10*, *Sox9*, *Sox8*, and *Hes1*. n=3-5 independent experiments. \*p<0.05 (t-test), error bars - standard error of the mean (s.e.m.).

**B.** The percentage of immature oligodendrocytes (RIP+) out of the total cell population (DAPI+) increased upon treatment with T3, but was not altered by VPA, as assessed by immunocytochemistry.

**C.** The total number of cells was not significantly affected by any of the treatments, as assessed by quantification of the number of DAPI+ cells. (B-C, n=3 independent experiments.)

**D.** Scheme of *Sox10/Hdac2/3* knockdown in differentiating NSCs. NSCs were differentiated for 3 DIV in absence of FGF-2 and in the presence of the different compounds. At DIV3, NSCs were lipofected with *Sox10/Hdac2/Hdac3* siRNA. Immunocytochemistry and qRT-PCR were performed with samples collected at DIV4 (1 DIV after lipofection = 1 DAT) and DIV 6 (3 DIV after lipofection = 3 DAT).



**Supplementary Figure S3**

**A.** Proliferating prenatal oligodendrocyte progenitors (Oli-neu cells) were co-lipofected with HDAC2 and/or HDAC3 siRNAs and a plasmid containing green fluorescent protein (GFP). Both siRNAs induced clear morphological changes with HDAC2 siRNA resulting in multiple short processes and HDAC3 siRNA rather to the appearance of thin, long processes. Scale bar: 60µm.

**B.** RT-qPCR results demonstrating *Mbp* and *Plp* mRNA levels in differentiating Oli-neu cells that were lipofected with control, HDAC2 and/or HDAC3 siRNA.


**C, D, E, F.** Chromatin from proliferating Oli-neu cells was cross-linked with 1% formaldehyde for 10 minutes as described in Experimental Procedures, and ChIPs were performed using antibodies against HDAC2, HDAC3, PolII, Histone H3 and the acetylated lysines H3K9, H3K14 and H4K16, followed by qPCR of regions on defined regions on the *Mbp* and *Sox10* loci.

**G.** RT-qPCR results demonstrating *Olig2* mRNA levels in proliferating Oli-neu cells that were lipofected with control, HDAC2 and/or HDAC3 siRNA. No increase in expression was observed.

**H.** RT-qPCR results demonstrating *Mbp*, *Plp*, and *Cnpase* mRNA levels in postnatal oligodendrocyte precursor (CG4) cells that were lipofected with control, HDAC2 and/or Sox10 siRNA.

**I.** RT-qPCR results demonstrating *Olig2* mRNA levels in NSCs that had been treated with vehicle, VPA and/or T3. No increase in expression was observed.

**A, B, G, H, I:** n=3-5 independent experiments. **C, D, E, F:** n=2-3 independent experiments. Error bars = S.E.M..



**Sox10 U2 enhancer sequence in mouse (mm10)/human (hg19)**

Conserved SOX\_Q6 binding sites in blue (analysis with ECR browser and RVISTA 2.0)  
 ChIP-qPCR U2 amplicon in red

```

mm10      10      20      30      40      50      60
          CACTTCTTCAGCCTCAGTTTCCCTCTCTGTAAACAGGGGTAATGTCTCCATAACC
hg19      10      20      30      40      50
          CACTCTCTGTGGTCTCAGTTTCCCTCT-ATAACACCGGG--GCTGTCTTCAGATC

mm10      70      80      90      100     110     120
          GCAGAGCCTCTCCAGCTGTGCTCCCTCTGTGACAGAGAG--TCGAGACAGAGGCAAG
hg19      70      80      90      100     110
          CCAAGGCCCTCCAGCTGTGCCATCTGCAACTGTGAGATTCTGAGACAGAGGAGGGA

mm10      130     140     150     160     170     180
          AGGCAGATGGGGCCCTCTTCCCGACCTCTCCCTGTCCCGAGGTCACCCAAA
hg19      120     130     140     150     160     170
          AGGCGGATGG--CCCTCTTCCCGACCGCTCTCTGTCTCCCGAGGTCACCCAAA

mm10      190     200     210     220     230
          GCGCCGCT--CCCGAGCTCCCTGGGACTCCCTGACGCTGACAGC-TGGGGAGACAATC
hg19      180     190     200     210     220     230
          GCGCCGCTCCCGGCTCCCTGGGACTCCCTGACGCTGACAGCCTGGTGGAGACAATT

mm10      240     250     260     270     280     290
          GGGTCTTTAGAGAAATACATTTTGGGCAATTTGCCATGACAGAGTGTTCCTTACC
hg19      240     250     260     270     280     290
          GGGTGTTTAGAGAAATACATTTTGGGCAATTTGCCATGACAGAGTGTTCCTTACC

mm10      300     310     320     330     340     350
          CTTTAAAGGCAGAGACAAAGACCTTCTGTGTCCCTGGGACGCTCTGGGAAGGGAC
hg19      300     310     320     330     340     350
          CTTTAAAGGCAGAGACAAAGAGTCTTCTGTGTCCCGAGGACGCTCTGGGAGGGGA


mm10      360     370     380     390     400     410
          GCAGCTGTA-GGGGCTGTGAC--CCTCCCTCCATCCAGTGGACATCCCGACA
hg19      360     370     380     390     400     410
          GCAGCTGTA-TGGGCTGTGAC--CCTCCCTCCATCCAGTGGACATCCCGACA

mm10      420     430     440     450     460     470
          CACAGCCCCGCTGTCCAGCCCGCCCGCCACAGAGGACAGCTGGACTTCCAGCCCTC
hg19      420     430     440     450     460
          CACCG-----CCACCGC-----CCCGAGAGAGACAGCCGACTTCCAGCCCTC

mm10      480     480     -----     500
          CCCCAGTTCCTACCCCGGCTGCTGTGAGGCTCCTGTGGCCCTGCTGCCCCAGCTCC
hg19      470     480     490     500     510     520
          CCCCAGTTCCTACCCCGGCTGCTGTGAGGCTCCTGTGGCCCTGCTGCCCCAGCTCC

mm10      510     520     530     540     550     560
          CTCCCACAGCTGCCCGAGGAGGAAAGTGTGCTGGTGGT-GGCACTGGGTGGGGA
hg19      530     540     550     560     570     580
          CCTC-CCAGCTGCCCGAGGAGGAAAGTGTGCTGGTGGTGGATGGACGGGGA

mm10      570     580     590     600
          GGGG--ACAGAGAGAAAGCATTCTCCACGTGTTGTGTG
hg19      570     580     590     600
          GGGGCTGCATGGAGAGACAGCGCTTCCATGTGGCCCGGGTG
  
```



**Supplementary Figure S4**

A. A conserved SOX2 binding site (blue) in the U2 enhancer (red) of the *Sox10* gene found in mouse and human.

B. A similar site detected by ChIP-Seq in embryonic stem (ES) cells.

Reference:  
 Chen et al. (2008) "Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 133, 1106-17.

CASTELO-BRANCO et al, SUPPLEMENTARY TABLE 1.  
Gene expression data underlying heatmap in Figure 2B.

| PEAK FOLD | ACC #    | DESCRIPTION  |
|-----------|----------|--|
| 25.14     | M37335   | proteolipid protein (myelin)   |
| 28.74     | M11533   | myelin basic protein   |
| 7.47      | M63801   | gap junction membrane channel protein alpha 1                                      |
| 4.84      | X16202   |  |
| 4.59      | V00746   | histocompatibility 2, K region   |
| 4.41      | M69069   | histocompatibility 2, D region locus 1   |
| 4.19      | A1117211 | histocompatibility 2, L region   |
| 3.79      | C78850   | RIKEN cDNA 1300007C21 gene   |
| 3.79      | L26836   | ATP-binding cassette, sub-family D (ALD), member 3                                 |
| 4.18      | L47480   | bone morphogenetic protein 4   |
| 5.14      | M28730   | tubulin, beta 4  |
| 4.00      | M16472   | proteolipid protein (myelin)   |
| 4.04      | AF031127 |  |
| 3.75      | K02236   | metallothionein 2  |
| 3.39      | U31566   | NK2 transcription factor related, locus 2 (Drosophila)                             |
| 3.12      | AJ223206 | scrapie responsive gene 1  |
| 3.16      | M26071   | coagulation factor III   |
| 3.52      | X52490   | histocompatibility 2, D region   |
| 2.79      | M25944   | carbonic anhydrase 2   |
| 2.78      | X01838   | beta-2 microglobulin   |
| 2.77      | X00246   | histocompatibility 2, D region locus 1   |
| 2.72      | AJ006474 | carbonic anhydrase 3   |
| 2.95      | AI847230 |  |
| 2.97      | AI851348 |  |
| 2.73      | U73521   | solute carrier family 1, member 1  |
| 2.60      | AI840267 | sirtuin 2 (silent mating type information regulation 2, homolog) 2 (S. cerevisiae) |
| 2.69      | J04627   | methylenetetrahydrofolate dehydrogenase (NAD+ dependent)                           |
| 2.35      | M21265   | stearoyl-Coenzyme A desaturase 1   |
| 2.24      | J02652   | malic enzyme, supernatant  |
| 2.42      | L06115   | CD9 antigen  |
| 2.58      | M18837   |  |
| 2.43      | M58156   | MHC (A.CA/J(H-2K-f) class I antigen  |
| 2.44      | AI850558 |  |
| 2.17      | M27134   | histocompatibility 2, K region locus 2   |
| 2.98      | AW060549 | RIKEN cDNA 13000007C21 gene  |
| 2.67      | AF017994 | mesoderm specific transcript   |
| 2.56      | M17327   |  |
| 2.69      | AI845796 | RIKEN cDNA 231000B05 gene  |
| 2.22      | AI842277 | insulin-like growth factor binding 3.  |
| 5.20      | U19582   | claudin 11   |
| 3.70      | M63801   | gap junction membran channel protein alpha 1                                       |
| 3.57      | L22144   | S100 protein, beta polypeptide, neural   |
| 3.44      | AB017270 | transmembrane protein with EGF-like and two follistatin-like domains               |
| 2         |          |  |
| 3.45      | AW046181 | serum/glucocorticoid regulated kinase  |
| 3.31      | U51000   | distal-less homeobox 1   |
| 3.05      | AI845514 | ATP-binding cassette, sub-family A (ABC1), member 1                                |
| 2.66      | AW125478 | protease, serine, 11 (igf binding)   |
| 2.67      | AI840191 | expressed sequence AW547365  |
| 2.28      | D83277   | RAB33A, member of RAS oncogene family  |

|       |          |   |
|-------|----------|---|
| 2.23  | AI001972 | inhibitor of DNA binding 4  |
| 2.21  | AW124983 | epidermal growth factor receptor pathway substrate 15                 |
| 2.19  | L12447   | insulin-like growth factor binding protein 5                          |
| 2.20  | AB017026 | cDNA sequence AB017026  |
| 2.18  | AI842472 |   |
| 2.23  | AI848201 | RIKEN cDNA 1700006H23 gene  |
| 2.33  | AF031127 |   |
| 2.17  | AW124196 | RIKEN cDNA 5530600A 18 gene   |
| 2.21  | X66449   | S100 calcium binding protein A6 (calcyclin)                           |
| 2.24  | AI847795 |   |
| 2.24  | U86090   | kinesin family member 5B  |
| 2.39  | U39738   | p21 (CDKN1A)-activated kinase 3                                       |
| 2.53  | AW122114 | RIKEN cDNA C0300448H19 gene   |
| 2.58  | AW061337 | adenylate kinase 4  |
| 2.27  | L49507   | cyclin G  |
| 2.22  | AW125874 | RIKEN CDNA 3010001M15 gene  |
| 2.23  | AW046627 |   |
| 2.16  | AI842065 | expressed sequence AU046135   |
| 2.23  | AW125390 | RIKEN cDNA 1110004C05 gene  |
| 2.26  | AA016517 | RIKEN cDNA 1500005102 gene  |
| 2.15  | AI844626 | glycine amidinotransferases (L-arginine glycine aminotransferas)      |
| 2.30  | AV347220 | endothelial differentiation sphingolipid G-protein-coupled receptor 1 |
| 2.35  | X05862   |   |
| -2.81 | AI851048 | RIKEN cDNA 1810030E20 gene  |
| -2.60 | AI854154 | DNA segment, Chr 9, Wayne State University 18, expressed              |
| -2.64 | AI853439 |   |
| -2.90 | X61397   | carbonic anhydrase-like sequence 1                                    |
| -4.24 | AA880275 | metallothionein-I activator   |
| -6.72 | AA874329 |   |
| -3.67 | L04961   | inactive X specific transcripts                                       |
| -7.34 | AW047207 | RIKEN cDNA 1810037I17 gene  |
| -4.75 | AI853444 | RIKEN cDNA 2610042L04 gene  |
| -3.77 | AI853444 | RIKEN cDNA 2610042L04 gene  |
| -6.33 | AI854020 | cysteine dioxygenase 1, cytosolic                                     |
| -4.03 | AF084642 | retinaldehyde binding protein 1                                       |
| -2.94 | AF000294 | peroxisome proliferator activated receptor binding protein            |
| -4.07 | AW228316 | RIKEN cDNA 2310046G15 gene  |
| -3.23 | AB028241 | casein kinase 1, epsilon  |
| -2.74 | AW258842 | RIKEN cDNA 2510049I19 gene  |
| -2.27 | U32329   | endothelin receptor type B  |
| -2.43 | AI325791 | expressed sequence AI507524   |
| -2.36 | U22399   | cyclin-dependent kinase inhibitor 1C (p57)                            |
| -2.73 | X15986   | lectin, galactose binding, soluble 1                                  |